Did the PREDIMED Trial Test a Mediterranean Diet?
Lawrence J. Appel, M.D., M.P.H., and Linda Van Horn, Ph.D., R.D.

The U.S. Dietary Guidelines recommend healthy dietary patterns — specifically, the Dietary Approaches to Stop Hypertension (DASH) diet and Mediterranean-style diets.¹ A persuasive body of evidence from observational studies has documented that Mediterranean-style diets are associated with a substantially reduced risk of cardiovascular disease.² Mediterranean diets are not a single dietary pattern, but they do have common features — an emphasis on vegetables, fruits, beans, nuts, seeds, breads, unrefined grains, and olive oil (but not necessarily extra-virgin olive oil); inclusion of fish and wine; and minimal intake of meats and full-fat dairy products.³ Such diets are rich in total, monounsaturated, and polyunsaturated fat and are lower in saturated fat.

In this issue of the Journal, Estruch and colleagues document that provision of extra-virgin olive oil or mixed nuts, in the context of a Mediterranean-style diet, substantially reduced the occurrence of cardiovascular disease.⁴ In brief, the Prevención con Dieta Mediterránea (PREDIMED) trial, conducted in Spain, randomly assigned 7447 persons at high risk for cardiovascular disease to one of three groups: participants who received advice on a Mediterranean diet and provision of extra-virgin olive oil, those who received advice on a Mediterranean diet and provision of mixed nuts, and those who received advice to reduce dietary fat (control diet). Extra-virgin olive oil is rich in polyphenols and monounsaturated fat, and mixed nuts are rich in polyphenols, monounsaturated fat, and polyunsaturated fat, including alpha-linolenic acid.

The primary end point was a composite of major cardiovascular events (myocardial infarction, stroke, or death from cardiovascular causes). Interim analyses prompted early termination of the trial. As compared with the control group, the two groups that received advice on a Mediterranean diet reduced the risk of cardiovascular disease by approximately 30%. For any therapy, including drug therapy, this magnitude of benefit is impressive; for a dietary intervention, such results are truly remarkable. Still, results might be exaggerated because early termination of trials tends to spuriously inflate estimated benefit.⁵

Central to the interpretation of the results of the PREDIMED trial is an understanding of achieved dietary changes. Despite advice to lower fat intake and limit consumption of olive oil and nuts, the control group did not achieve a low fat intake. Indeed, the control group appeared to consume a variant of the Mediterranean diet. At the end of the trial, total fat was 37% of energy intake in the control group and 41% of energy intake in the other two groups; saturated-fat intake was low and similar in the three groups, approximately 9% of energy intake. In the group receiving extra-virgin olive oil, the additional 4 percentage points in energy intake from fat resulted mostly from increased monounsaturated-fat intake. In the group receiving mixed nuts, the additional 4 percentage points resulted from increases of approximately 2 percentage points in both monounsaturated and polyunsaturated fat.

The most striking differences between the randomized groups resulted from the supplemental foods, not the dietary advice, which led to modest between-group differences (as compared with the control group) in legume and fish consumption and no major differences in intake of other nutrients and food groups. The amount of extra-virgin olive oil and nuts provided to participants and their households was substantial (1 liter of extra-virgin olive oil per week and 30 g of mixed nuts per day). At the end of follow-up, the average energy intake from...
of a Mediterranean-style diet, increased con-
supplemental foods. Specifically, in the context
of the PREDIMED trial relate primarily to the
studies. Our sense is that the policy implications
are exceedingly dependent on blood pressure. This re-
sult is concordant with those of observational
effects. But what are its policy impli-
cations? The PREDIMED trial is neither a pure
test of a Mediterranean-style diet nor a pure test of
beneficial effects on cardiovascular disease.

The impressive results of the PREDIMED trial
confirm that changes in diet can have powerful,
beneficial effects. But what are its policy impli-
cations? The PREDIMED trial is neither a pure
test of a Mediterranean-style diet nor a pure test of
extra-virgin olive oil and nuts. Interpretation
of the PREDIMED trial is similar in complexity
to that of the Lyon Diet Heart Study, which tested
provision of a margarine rich in alpha-linolenic
acid, coupled with brief advice to consume a
Mediterranean diet.9

Policy makers1 already recommend consump-
tion of a Mediterranean-style diet on the basis of
a persuasive body of evidence from observational
studies. Our sense is that the policy implications
of the PREDIMED trial relate primarily to the
supplemental foods. Specifically, in the context
of a Mediterranean-style diet, increased con-
sumption of mixed nuts or substitution of regu-
lar olive oil with extra-virgin olive oil has bene-
ficial effects on cardiovascular disease.

Still, there are many unanswered questions.
Will the benefits of extra-virgin olive oil and
mixed nuts accrue to persons consuming other
diets? Does high consumption of extra-virgin
olive oil and mixed nuts lead to weight gain?
Can the benefits of extra-virgin olive oil and
mixed nuts occur at lower doses?

Disclosure forms provided by the authors are available with the
full text of this article at NEJM.org.

From the Welch Center for Prevention, Epidemiology, and
Clinical Research, Johns Hopkins University, Baltimore (L.J.A.); and
the Department of Preventive Medicine, Feinberg School of
Medicine, Northwestern University, Chicago (L.V.H.).

1. Department of Agriculture, Center for Nutrition Policy and
Promotion. United States dietary guidelines for Americans, 2010
(http://www.dietaryguidelines.gov).
2. Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on
benefits of adherence to the Mediterranean diet on health: an
updated systematic review and meta-analysis. Am J Clin Nutr
2010;92:1189-96.
TL. Benefits of a Mediterranean-style, National Cholesterol
Education Program/American Heart Association Step I Dietary Pat-
of cardiovascular disease with a Mediterranean diet. N Engl J
trials early for benefit and estimation of treatment effects: sys-
tematic review and meta-regression analysis. JAMA 2010;303:
1180-7.
tion, plasma oleic acid, and stroke incidence: the Three-City
Trichopoulou A. Relation of the traditional Mediterranean diet
to cerebrovascular disease in a Mediterranean population. Am J
8. Sherzai A, Heim LT, Bootbhy C, Sherzai AD. Stroke, food
groups, and dietary patterns: a systematic review. Nutr Rev 2012;
70:423-35.
of a Mediterranean-style diet on cardiovascular risk factors:
10. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J,
Mamelle N. Mediterranean diet, traditional risk factors, and
the rate of cardiovascular complications after myocardial in-
farction: final report of the Lyon Diet Heart Study. Circulation

DOI: 10.1056/NEJMe1301582
Copyright © 2013 Massachusetts Medical Society.

Efficiently Killing a Sugar-Coated Yeast
John R. Perfect, M.D.

With the inclusion in this issue of the Journal of
the study by Day et al. on the treatment of crypto-
coccal meningitis, the Journal has provided the
medical community with a trilogy of studies for
the understanding of combination therapy with
amphotericin B and flucytosine for cryptococcal

The New England Journal of Medicine
Downloaded from nejm.org by NICOLETTA TORTOLONE on April 4, 2013. For personal use only. No other uses without permission.
Copyright © 2013 Massachusetts Medical Society. All rights reserved.